Presentation will showcase Patheon’s strategic plan for manufacturing selective cytostatic tablets at the Bourgoin multiproduct facility
Katherine Griotier, a leading regulatory expert at Patheon, the pharmaceutical services business owned by DPx Holdings, was selected by the French Agency to be one of two industry speakers at the 2014 PIC/S Annual Seminar in Paris from 22 – 24 October, focusing on the topic of dedicated facilities in the CDMO industry.
Griotier will present a case study highlighting Patheon’s expertise in handling high potency compounds at its recently built facility in Bourgoin, France. Patheon’s Bourgoin site specialises in solid oral dosage forms, including Investigational Medicine Products. In 2010, the site near Bourgoin began an innovative approach to handling highly potent compounds in its product development services suite. As part of its industrial strategy, the site is growing capabilities in innovative fields relating to the handling of potent compounds.
Griotier’s presentation will showcase Patheon’s strategic plan for manufacturing selective cytostatic tablets at the Bourgoin multiproduct facility and highlight key elements supporting substantial changes in manufacturer’s licensing due to changes in domestic regulation classification.
The PIC/S Annual Seminar is hosted by France and the National Security Agency of Medicines and Health Products. Approximately 120 PIC/S inspectors from 46 participating countries including the US, Canada and Japan, as well as partners from European Medicines Agency and the World Health Organization will be in attendance.